Physician profile
Jennifer L Mylod
NPI 1053725879
$131,182.76
in general payments reported to CMS, 2019-2025
33 companies · $32K in 2025
The $32K reported for 2025 was more than what 99% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14K · 2022: $30K · 2023: $22K · 2024: $34K · 2025: $32K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Consulting Fee: $16K · Food and Beverage: $12K · Travel and Lodging: $9,073 · Education: $97.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $49,888.00 |
| Consulting Fee | $15,855.00 |
| Food and Beverage | $12,317.92 |
| Travel and Lodging | $9,072.59 |
| Education | $97.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $45,063.43 | 2021-2025 | |
| Janssen Biotech, INC. | $36,712.74 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Janssen Scientific Affairs, LLC | $25,698.92 | 2021-2024 | Tremfya, Simponi Aria, Stelara |
| Boehringer Ingelheim Pharmaceuticals, INC. | $7,311.50 | 2022-2025 | Ofev, Cyltezo |
| Amgen INC. | $2,964.21 | 2021-2025 | Krystexxa, Enbrel, Otezla |
| Novartis Pharmaceuticals Corporation | $2,850.72 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,892.94 | 2021-2025 | Sotyktu, Orencia |
| Ucb, INC. | $1,647.28 | 2021-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $1,246.22 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $1,147.91 | 2023-2025 | Acthar |
| Horizon Therapeutics Plc | $1,134.17 | 2021-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $903.65 | 2021-2025 | Lupkynis |
| Lilly USA, LLC | $737.79 | 2021-2024 | Taltz, Zepbound |
| Glaxosmithkline, LLC. | $417.86 | 2021-2025 | Benlysta |
| Astrazeneca Pharmaceuticals Lp | $249.64 | 2021-2025 | Saphnelo, Andexxa |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $179.99 | 2022-2024 | Purified Cortrophin Gel |
| Fresenius Kabi USA, LLC | $158.41 | 2023-2024 | Idacio, Tyenne |
| Radius Health, INC. | $156.01 | 2022-2024 | Tymlos |
| Biosense Webster, INC. | $122.01 | 2024 | Carto 3 |
| Genentech USA, INC. | $104.81 | 2021-2023 | Actemra, Rituxan |
| Alexion Pharmaceuticals, INC. | $63.32 | 2021-2024 | Ultomiris |
| Actelion Pharmaceuticals US, INC. | $59.67 | 2022-2024 | Uptravi, Opsumit |
| Kyowa Kirin, INC. | $51.08 | 2024 | Crysvita |
| Sobi, INC | $49.13 | 2025 | |
| Tonix Medicines, INC. | $47.93 | 2025 | Tonmya |
| Genzyme Corporation | $47.08 | 2021-2024 | |
| Octapharma USA, INC. | $39.56 | 2025 | Octagam Immune Globulin (Human) |
| Ferring Pharmaceuticals INC. | $31.81 | 2021-2022 | |
| Pacira Therapeutics, INC. | $20.01 | 2021 | |
| Celltrion USA INC. | $19.25 | 2023 | Yuflyma |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.03 | 2021 | |
| Scilex Pharmaceuticals INC. | $17.76 | 2024 | |
| Abbott Laboratories | $16.92 | 2025 | Proclaim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Mylod listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.